Discovery of Dioxino[2,3-f]quinazoline derivative VEGFR-2 inhibitors exerting significant antipro-liferative activity in HUVECs and mice
- Eur J Med Chem. 2019 Aug 1:175:349-356. doi: 10.1016/j.ejmech.2019.04.015.
- 1. College of Life Science and Bioengineering & Beijing Key Laboratory of Environmental and Oncology, Beijing University of Technology, Beijing, 100124, China.
- 2. Beijing Scitech-MQ Pharmaceuticals Limited, Beijing 101320, China.
- 3. Guangxi Key Laboratory Cultivation Base for Polysaccharide Materials and Modifications, School of Marine Sciences and Biotechnology, Guangxi University for Nationalities, Nanning, 530008, China.
- 4. College of Life Science and Bioengineering & Beijing Key Laboratory of Environmental and Oncology, Beijing University of Technology, Beijing, 100124, China. Electronic address: [email protected].
Twelve 2,3-dihydro-[1,4]-dioxino[2,3-f]quinazoline derivatives were designed and evaluated as vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitors. The most half-maximal inhibitory concentration (IC50) values of them were less than 10 nM. Among these compounds, 13d displayed highly effective inhibitory activity against VEGFR-2 (IC50 = 2.4 nM) and excellent antiproliferative activities against human umbilical vein endothelial cells (HUVECs) (IC50 = 1.2 nM). When anti-tumor animal experiments were carried out in mice, the tumor almost disappeared (TGI = 133.0%) after six days of administration of 13d. Therefore, 13d was a potential and effective Anticancer agent. The binding conformations were respectively compared between VEGFR-2 with 13d and leading compound lenvatinib, and shows that they have similar binding modes.